Project Development

GREGORY W. HENKEL, PH.D.

Carlsbad, CA ***** Home: 760-***-****

abner6@r.postjobfree.com Cell: 760-***-****

R&D Leadership - Pharmaceuticals and Biotechnology

Results and people oriented R&D leader who combines vision, passion,

knowledge, communication, and motivation to lead successful teams. Fifteen

years of research experience across oncology, immunology, stem biology and

multiple target classes including kinases, GPCRs, and proteases.

Experience in managing and developing scientists and leading cross-

functional drug discovery teams.

Key competencies include:

. Cellular and molecular biology

. Translational biology

. High-throughput screening

. Early research discovery

. Biomarker development

. Leadership/Team building

. Strategic planning and implementation

. Leading external collaborations

RESEARCH EXPERIENCE

BioResearch Consulting, San Diego, CA 2009-present

Principal

Translational biology and preclinical R&D management across multiple

therapeutic areas including oncology, immunology/inflammation and neurology

VERTEX PHARMACEUTICAL, INC., San Diego, CA 2001 - 2008

(Acquired Aurora Biosciences in 2001.)

Director of Biology 2007 - 2008

Provided executive leadership to a group of 10 Ph.D. and non-Ph.D.

scientists responsible for in vitro pharmacology across multiple early and

lead discovery projects.

. Worked closely with project heads to provide scientific input and hands

needed to help projects advance.

o Directed development of an assay to measure target activity in primary

human T-cells for Multiple Sclerosis project. Enabled advancement of

project to full lead discovery.

o Led development of a mouse ES cell differentiation protocol to

cortical neurons. Completed deliverable milestone for a collaborative

partner in Huntington's disease.

o Wrote white paper on approaches to tackle Huntington's disease

including regeneration and directly targeting biosynthesis and

degradation of the mutant htt protein. Concepts incorporated into

research effort.

. Led new instrument and technology initiative to enhance biology research.

o Acquired Luminex Multiplex Instrument - data enrichment, enhanced

productivity and saved money on disposable reagent costs.

o Confocal microscope added to 2009 budget to help build neurology

platform.

o Convinced internal engineers to build automated Western Blot

processing apparatus which helped to improve productivity.

. Managed development of internal web page for new target evaluation and

prioritization that included papers, presentations and priority scores.

System helped improve transparency/efficiency in decision-making and

incorporated at other sites.

. Coaching and mentoring led to development of scientific leaders in group

that could work independently and lead projects.

GREG W. HENKEL, PH.D. Cell: 760-***-**** Page Two

Research Fellow I 2005 - 2007

. Portfolio management: Led group of scientists to develop research

strategy around pain and neurodegenerative diseases. Coordinated

research strategy with clinical and commercial representatives and

outside consultants.

o Established pain R&D strategy including clinical path and

commercialization.

o Led team in evaluating and prioritizing new pain targets.

. Oversaw early research efforts.

. Two of six targets advanced to lead discovery.

o Identified Huntington's disease as entry point into neurodegenerative

disease.

. Served as Project Head across three different sites to develop a GSK-3

antagonist for regeneration and repair in stroke and spinal cord injury.

o Identified lead aminopyridine candidate and novel biology.

o Candidate being evaluated but showed positive response in stroke

model.

o Co-author on patents (see reference).

Group Leader, Biology 2003 - 2005

. Project and Biology Head on a multifunctional cancer drug discovery team

across two sites that resulted in two preclinical diaminotriazole

candidates and $10M in revenue for Vertex.

o Completed project from early discovery through lead candidate

selection in 18 months.

o Received Outstanding Performance Award and 1,000 shares of Vertex

Stock.

o Co-author on chemistry patents (see reference).

Principal Scientist 2001 - 2003

. Guided a team of scientists building a panel of cell-based signaling

pathway assays (CellSensors) to be used as functional screening tools for

orphan genes, compound profiling and SAR, primary and secondary screens.

o Some CellSensor assays bundled with other reagents and licenses and

sold to Invitrogen during transition from Aurora to Vertex as part of

$95M package.

o Managed external collaboration to profile orphan gene products against

CellSensor panel. Realized $750K in revenue.

AURORA BIOSCIENCES CORPORATION, San Diego, CA 1999 - 2001

Senior Scientist

Provided leadership to a team of scientists on externally funded projects.

. Developed and delivered a high-throughput cell assay for Pfizer on time

and meeting desired specifications.

. NCI sponsored gene-profiling project using Aurora's Gene-Trap Technology.

o Achieved milestones and realization of revenue 6 months ahead of

schedule.

THE BURNHAM INSTITUTE, La Jolla, CA 1994 - 1999

Postdoctoral Fellow in laboratory of Dr. Richard Maki, Ph.D.

. Studied role of the ets transcription factor PU.1 in regulating

hematopoiesis.

. Received NIH National Research Service Award (1996 - 1999).

. Authored and co-authored eight papers.

EDUCATION

Ph.D., Immunology - Oregon Health Sciences University, Portland, OR

B.S., Biochemistry - California Polytechnic State University, San Luis

Obispo, CA

GREG W. HENKEL, PH.D. Cell: 760-***-**** Page Three

PUBLICATIONS

Heidary, DK, Huang, G, Zhou, J, Davies, R, Namchuk, M, Ball, ED and Henkel,

GW. FLT3 inhibitors for the treatment acute myelogenous leukemia: Primary

patient blasts reveal the importance of inhibiting FLT3 and c-KIT receptor

tyrosine kinases (in preparation).

Heidary, DK, Huang, G, Ma, J, Davies, R, Chen, G, Zhou, J, Yao, M, Stack J,

Namchuk M, Ball, ED and Henkel, GW. Selective targeting of survival

pathways: Inhibition of FLT3 as a treatment for acute myeloid leukemia (in

preparation).

Stack, JH, Beaumont, K, Larsen, PD, Straley, KS, Henkel, GW, Randle, JC and

Hoffman, HM. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the

hypersensitive response to an inflammatory stimulus in monocytes from

familial cold autoinflammatory syndrome patients, J Immunol 175: 2630-2634,

2005.

Henkel, GW, McKercher, SR and Maki, RA. Identification of three genes up-

regulated in PU.1 rescued monocytic precursor cells: International

Immunology, 14: 723-732, 2002.

Hural JA, Kwan M, Henkel G, Hock MB, Brown MA. An intron transcriptional

enhancer element regulates IL-4 gene locus accessibility in mast cells: J

Immunol, 165: 3239-3249, 2000.

McKercher, SR, Henkel, GW and Maki, RA. The transcription factor PU.1 does

not regulate lineage commitment but has lineage-specific effects: Journal

of Leukocyte Biology, 66: 727-732, 1999.

Lichanska, AM, Browne, CM, Henkel, GW, Murphy, KM, Ostrowski, MC,

McKercher, SR, Maki, RA and Hume, DA. Differentiation of the mononuclear

phagocyte system during mouse embryogenesis: The role of transcription

factor PU.1. Blood, 94: 127-138, 1999.

Henkel, GW, McKercher, SR, Leenen, PJM and Maki, RA. Commitment to the

monocytic lineage occurs in the absence of the transcription factor PU.1.

Blood, 93: 2849-2858, 1999.

Yamamoto, H, Flannery, ML, Kupriyanov, S, Pearce, J, McKercher, SR, Henkel,

GW, Maki, RA, Werb, Z and Oshima, RG. Defective trophoblast function in

mice with a targeted mutation of Ets2. Genes and Development, 12: 1315-

1326, 1998.

McKercher, SR, Torbett, BE, Anderson, KL, Henkel, GW, Vestal, DJ,

Baribault, H, Klemsz, M, Feeney, AJ, Wu, GE, Paige, CJ and Maki, RA

Targeted disruption of the PU.1 gene results in multiple hematopoietic

abnormalities. EMBO J., 15: 5647-5658, 1996.

Henkel, GW, McKercher, SR, Yamamoto, H, Anderson, KL, Oshima, RG and Maki,

RA PU.1 but not Ets-2 is essential for macrophage development from

embryonic stem cells. Blood, 88: 2917-2926, 1996.

Beom-Seok, Y, Hauser, CA, Henkel, G, Colman, MS, Van Beveren, C, Stacey,

KJ, Hume, DA, Maki, RA and Ostrowski, MC Ras-mediated phosphorylation of a

conserved threonine residue enhances the transactivation activities of c-

Ets1 and c-Ets2. Mol. Cell Biol., 16: 538-547, 1996.

Weiss, DL, Tara, D, Timmerman, LA, Henkel, G and Brown, MA, Nuclear factor

of activated T cells is associated with a mast cell IL-4 transcription

complex. Mol. Cell Biol., 16: 228-235, 1996.

GREG W. HENKEL, PH.D. Cell: 760-***-**** Page Four

Henkel, G and Brown, MA, PU.1 and GATA: Components of a mast cell specific

interleukin-4 intronic enhancer. Proc. Natl. Acad. Sci., 91: 7737-7741,

1994.

Henkel, G, Weiss, D.L, McCoy, R, Deloughery, T, Tara, D, and Brown, M. A, A

DNase I-hypersensitive site in the second intron of the murine IL-4 gene

defines a mast cell-specific enhancer. Journal of Immunology, 149: 3239-

3246, 1992.

Book Chapter

Henkel, GW, Live Cell Assays: Tools for Functional Genomics. Genomic

Technologies: Present and Future, David J Galas (Ed.), Caister Academic

Press, 2002.

PATENTS

WO2004046120/US7279469 Diaminotriazoles Useful as Inhibitors of Protein

Kinases

WO2008112646/WO2008112651 Aminopyridines Useful as Inhibitors of Protein

Kinases

References upon request

Contact this candidate